anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The novel positively charged pro-drugs of retinoids and retinoid-like compounds in the general formula (31) &#39;Structure 31&#39; were designed and synthesized. The compounds of the general formula (31) &#39;Structure 31&#39; indicated above can be prepared from retinoic acids and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N&#39;-Dicyclohexylcarbodiimide, N,N&#39;-Diisopropylcarbodiimide, O-(Benzotriazol-1-yl)-N,N,N&#39;,N&#39;-tetramethyluronium tetrafluoroborate, O-(Benzotriazol-1-yl)-N,N,N&#39;,N&#39;-tetramethyluronium hexafluorophosphate, Benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs in water, but also bonds to the negative charge on the phosphate head group of membranes. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the prodrug. When the molecules of membrane move, the membrane may &#39;crack&#39; a little bit due to the bonding of the prodrug. This will let the prodrug insert into the membrane. At pH 7.4, only about 99% of amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the prodrug and the phosphate head group of membrane will disassociate, and the prodrug will enter the membrane completely. When the amino group of the prodrug flips to the other side of the membrane and thus become protonated, then the prodrug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. The results suggest that the pro-drugs diffuse through human skin -350 times faster than do retinoids and retinoid-like compounds. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any retinoids and retinoid-like compounds-treatable conditions in humans or animals. The prodrugs can be administered transdermally for any kind of medical treatments and avoid most of the side effects of retinoids and retinoid-like compounds. Controlled transdermal administration systems of the prodrug enables retinoids and retinoid-like compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of retinoids and retinoid-like compounds. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.
PROBLEM TO BE SOLVED: To obtain the subject highly stable preparation free from any problem in terms of safety such as skin irritancy and sensitization, and effective for improving skin conditions and treating skin inflammation and wound, by including a specific salicin and an α-hydroxy acid (salt, derivative). SOLUTION: This preparation for external use for skin is obtained by including (A) salicin of the formula and (B) an α-hydroxy acid (salt, derivative) [e.g. α-hydroxyacetic acid (or α-hydroxyglycolic acid)]. The ingredient A may be a synthetic product, or naturally-occurring matter and esp. extract therefrom, or a salicin-contg. mixture or salicin itself. Salicin is rich in the barks, leaves and female flowers of plants belonging to the genus Saliceae. The extractive solvent for obtaining Saliceae plant extract is pref. water, methanol, ethanol, 1,3-butylene glycol or the like. Formulation of the ingredients A and B each at &lt;=5 wt.% is enough for this preparation.
PURPOSE:A purified blood derived from pig blood, obtained by treating a blood plasma separated from a pig blood with an ultrafiltration membrane for a given molecular weight range, and removing a salt, low-molecular weight protein, etc., capable of exhibiting an antimicrobial activity and an antibody value against pathogenic coliform bacilli, effective for preventing diseases caused by coliform bacilli of newborn animals. CONSTITUTION:A fresh blood collected from a pig body by the direct blood collecting method while avoiding the contact with air is rapidly cooled to a temperature at which the multiplication of microorganisms will not occur, e.g. about 4-5 deg.C. The resultant cooled blood is then centrifuged at &lt;=5,000r.p.m. rotational frequency to give a supernatant fraction, which is then ultrafiltered through a filtration membrane for 6,000-13,000 fractionated molecular weight while being kept at a low temperature to purify the blood plasma component. Preferably, the removal ratio of foreign materials in the purification treatment is about 70-90%. The resultant purified concentrated liquid is then dried into powder by the freeze-dryig method, etc. and give the aimed purified blood plasma containing albumin and total globulin in (40-50):(50-60) ratio between the albumin and the total globulin in the whole protein. An antibiotic substance &#39;&#39;Colistin &#39;&#39; is added to the purified blood plasma and used together to give an artificial milk for animals.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an isolated nucleic acid molecule encoding a soluble protein binding to IL-TIF/IL-22.  &lt;P&gt;SOLUTION: The present invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins and uses of the protein are also described. The isolated nucleic acid molecule encoding the soluble protein binding to IL-TIF/IL-22 is provided, wherein complementary nucleotide sequences of the isolated nucleic acid molecule hybridize to nucleic acids comprising a plurality of specific sequences under stringent conditions.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Methods of inhibiting Barrett&#39;s esophagus and/or adenocarcinoma in a subject are provided. In a particular embodiment, the method comprises administering at least one composition comprising at least one zinc compound and at least pharmaceutically acceptable carrier to the esophagus of the subject. The zinc may be a pharmaceutically acceptable salt of zinc, such as zinc gluconate. The zinc may be administered, for example, orally, topically, or by a implantable medical device. In a particular embodiment, the methods further comprise administering at least one analgesic, anesthetic, or other therapeutic agent or therapy for the treatment of Barrett&#39;s esophagus. The method may further comprise monitoring the progression of Barrett&#39;s esophagus in the subject.
(EN): [Problem] To provide a compound useful as a pharmaceutical composition for prevention and/or treatment of diseases such as schizophrenia. [Solution] The inventors developed the present invention upon investigating a pharmaceutical composition having effects as a GABAB positive allosteric modulator (effects as a PAM), for preventing/treating diseases such as schizophrenia, and confirming that a sulfur-containing bicyclic compound has effects as a GABAB PAM. This sulfur-containing bicyclic compound has effects as a GABAB PAM and can be used as a preventive and/or therapeutic agent for diseases such as schizophrenia. (In the formula, X represents CH, R represents a lower alkyl, R represents a lower alkyl, R represents -H, R4 represents -H, ring A is a cyclohexane ring, RY represents a group represented by formula (III), Y represents NH, etc., and RL represents a lower alkyl.) (FR): L&#39;invention concerne un compose utile en tant que composition pharmaceutique pour la prevention et/ou le traitement de maladies telles que la schizophrenic. Les inventeurs ont mis au point la presente invention en etudiant une composition pharmaceutique presentant des effets de modulateur allosterique positif de GABAB (les effets d&#39;un РАМ), pour la prevention et/ou le traitement de maladies telles que la schizophrenie, et en confirmant qu&#39;un compose bicyclique contenant du soufre presente des effets egaux a un РАМ de GABAB. Ce compose bicyclique contenant du soufre presente des effets en tant que РАМ de GABAB et peut etre utilise comme agent preventif et/ou thirapeutique pour des maladies telles que la schizophrenie. (Dans la formule, X).
PURPOSE:The titled uniform and stable agent, obtained by incorporating an aqueous solution of pantethine which is an ameliorant of lipid metabolism and tocopherol acetate which is an ameliorant of peripheral blood stream with a specific glycerol ester of a fatty acid in a specific amount and having good formulating efficiency. CONSTITUTION:An agent for filling in a soft capsule obtained by incorporating (A) a 70-90% aqueous solution of pantethine and (B) tocopherol acetate (hereinafter abbreviated to.E.) with (C) a glycerol ester of a fatty acid with &gt;=40-&lt;60% caprylic acid monoglyceride content as an excipient. The compounding ratio of the respective components is 0.25-1 weight ratio of the components (A) and (B) to the component (C). The use of the component (C) as an excipient provides a clear agent containing the pantethine and V.E. which has not been available in the past. Thereby, the agent can be formulated as one grain soft capsule.
A method of reducing respiratory alkalosis (high blood pH) and enhancing productivity (rate of weight gain) in poultry during periods of chronic or acute heat stress (high heat and humidity) involving the steps of supplementing the birds&#39; diet (feedstuffs and/or water) with acids (hydrogen ion donor) and bicarbonate donors (NaHCO3) or supplementing the birds&#39; drinking water with additional potassium ion (e.g. KCl or K2CO3) and/or ammonium chloride with or without NaHCO3 and ascorbic acid. The addition of an acid donor as a poultry feed or water additive and the use of additional potassium in the drinking water significantly reduces the alkalosis induced mortality rate and enhances the rate of weight gain (up to 30 percent). By including NaHCO3 in the feed ration, the rate of gain is further enhanced (an additional 9 percent). The further intention addition of a sodium free, chloride ion donor also promotes increased rate of gain. The use of a H2 antagonist (cimetidine) to reduce stomach acid production is also beneficial to increase growth rate and mortality by reducing blood pH.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide allergic proteins of a natural rubber latex in substantially purified form, and to provide a method for producing the proteins and the use of the proteins.  &lt;P&gt;SOLUTION: The assaying method for qualitatively and quantitatively assaying levels of the allergic proteins in the natural rubber latex or a latex product involves using the allergic proteins in combination with a monoclonal antibody developed against the allergic proteins. The assaying method for identifying and/or determining the antibody which mediates the allergic reaction induced by the natural rubber latex, in blood or a blood product, and an in vivo or in vitro diagnostic test method using the allergic proteins are also provided. The allergens are also used as a desensitization agent when treating the latex protein allergy. The method for removing the allergic proteins from the latex product is also provided.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To obtain the subject cosmetic having excellent extension, simply applicable, capable of naturally correcting a skin color and finishing a beautiful skin with a transparent feeling by making the cosmetic include a color pigment in a specified ratio and making the pigment have an appearance color with a lightness and a chroma in prescribed ranges. SOLUTION: This cosmetic comprises (A) 0.05-2.4 wt.% of a colored pigment and has an appearance color with 3.0-9.0 lightness and 1.5-10.0 chroma in the Munsell color system. The component A contains preferably 1-95 wt.% of titanium oxide. Preferably the cosmetic contains (B) spherical power (such as spherical silica, spherical nylon, etc.), and further (C) 0.1-20 wt.% of powder having 1.6-1.8 refractive index, &gt;=70% scattering transmittance when formed into a thin film having 25 μm thickness in 20% powder concentration and &gt;=80% total transmittance (preferably aluminum oxide of laminar structure, barium sulfate, etc.), or (D) 0.1-20% colorable powder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new antimicrobial polypeptide and methods of use.  &lt;P&gt;SOLUTION: The composition of a substance including a lantibiotic mutacin 1140 which is substantially free from bacterial host. The antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic dentifrice.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
NEW MATERIAL:The propanol derivative of formula I (R is 10-24C alkyl). EXAMPLE:3-Octadecyloxy-2-amino-1-trityloxypropane. USE:An antitumor agent exhibiting remarkable antitumor activity against e.g. leukemia, solid carcinoma, etc. It has physical and chemical stability and is free from side effects such as drop of blood pressure. Dose: preferably about 50mg-2g daily for adult. PREPARATION:The compound of formula I can be prepared by reacting the compound of formula II with the compound of formula III (R&lt;1&gt; is 1-4C alkyl).
The invention comprises cryptoaescin, a water-soluble saponin derivable from extracts of horse-chestnut, having an empirical formula C59H94 O27.H2O, a molecular weight of 1253, and containing besides one mole of cryptoaescigenin, one mole each of a -methyl-b -hydroxy-butyric acid, acetic acid, glucuronic acid, glucose and xylose as well as arabinose, said cryptoaescin being convertible by isomerisation from one form, viz. cryptoaescin A, m.pt 218-20 DEG C., into another, viz cryptoaescin B, m.pt 220-1 DEG C., and a process for the isolation of the saponin from an aqueous or aqueous-alcoholic extract of horse-chestnut from which cholesterol-precipitable saponins have been removed, by acidification, preferably to a pH&lt;2, and recovery of cryptoaescin from the resulting precipitate and/or from the solution freed from the precipitate. The recovery step is preferably effected by extraction with an organic solvent, evaporation of the purified extract, extraction of the residue with water, treatment of the solution with a cation exchanger (if the organic extract was purified with alumina), extraction with butanol, evaporation of the butanol extract, treatment of the residue with methanol, treatment of the extract with charcoal and finally evaporation of the solvent to yield cryptoaescin A. The isomerisation of cryptoaescin A to cryptoaescin B is carried out by boiling in aqueous solution.ALSO:Cryptoaescin, a homogeneous water-soluble saponin isolated from horse chestnut extracts and exhibiting a strong action on the blood vascular system and diuretic and anti-histaminic properties, may be formulated with a non-toxic carrier for administration by injection.  Cryptoaescin exists in two isomeric forms, cryptoaescin A, which is non-haemolytic, and cryptoaescin B, which causes a harmless degree of haemolysis, and may be used to enrich an aqueous or aqueous-alcoholic horse chestnut extract from which the cholesterol-precipitatable saponins have been removed by treatment with cholesterol.  The horse chestnut extract freed from all saponin components, including cryptoaescin, is also useful therapeutically owing to the presence of other active constituents, notably flavorized compounds, e.g. flavonol glycosides.
A system for orthodontic treatment planning. The system comprises a processor and memory. Computer-program instructions cause the system to display a user interface on a display. The user interface is for a user to input a prescription for treatment of the patient. The user interface provides a plurality of commands for selection. Each command is a one-word instruction, a two-word instruction, or a three-word instruction based on orthodontic nomenclature. The system receives selected two or more of the plurality of commands into the prescription for treatment. The two or more selected commands are to be applied according to a predetermined protocol to the patient&#39;s teeth. A database is configured to receive the prescription for treatment of the patient and to contain a plurality of other prescriptions for treatment of other patients. The database is configured to receive a plurality of other prescriptions from a plurality of users of the system.
The present invention relates to an osteological traditional Chinese medicine which is prepared from 25 traditional Chinese medicines, such as angelica, safflower, sappanwood, frankincense, etc. The effective rate of The present invention is high, the total effective rate can reach 100%, and the healing rate is about 99%. The present invention has the advantages of short course of treatment, obvious effect and no recurrence after healing. Serious patients can be healed in 20 days, and ordinary patients can be healed in about 10 days. The present invention can reach the special functions, namely reaches five nourishments, such as nourishing blood, nourishing qi, nourishing kidneys, nourishing sperma, nourishing power, etc., and has the obvious effect on relieving pain and removing swelling. The present invention has the advantages of convenient admission, simple preparation, reliable technology, low cost, easy acquirement of medicine sources and obvious treatment effect, and furthermore, ordinary patients only use several hundreds of yuan to be healed. The medicine obviously lightens patients&#39; pain after being taken by the patients, the patients can naturally fall asleep, and furthermore, the medicine has the functions of strengthening the body, regenerating muscles, eliminating swelling and relieving pain.
PURPOSE: To obtain a polymerized allergen reduced in allergenicity while retaining the complete antigenicity of the allergen by mixing glutaric dialdehyde with a solution of a freeze-dried high-molecular weight ingredient of an active allergen extract under specific conditions. CONSTITUTION: A freeze-dried high-molecular weight ingredient from a homogeneous allergenic source material extracted with distilled water or an aqueous buffer solution is dissolved at 14-16mg/mL concentration in a phosphoric acid buffer solution at pH 7.4 and the resultant solution, as necessary, is clarified by centrifugation. The obtained transparent solution is then stirred at ambient temperature on a magnetic stirrer and a newly prepared 25% solution of glutaric dialdehyde is added thereto at 17-19μL ratio based on 1mL solution of the allergen. The resultant mixture solution is stirred at ambient temperature for 6hr and the reaction is terminated with glycine or other monoamino acids. A polymerized and a cross-linked product having &gt;100,000 Da molecular weight is then obtained according to a dialysis with a tangenitial flow and/ore molecular sieving.  The prepared allergen is useful for treating pollen hay fever.
PURPOSE:To obtain a mutagenicity inhibitor, containing a water-insoluble compound formed by peroxidase reaction of a compound having a phenylpropane skeleton as an active ingredient. CONSTITUTION:A mutagenicity inhibitor obtained by dissolving a compound selected from isoeugenol, coniferyl alcohol and ferulic acid in a water-miscible organic solvent in an amount of 5-50 times based on the compound, then mixing the above-mentioned solution with water adjusted to pH 4-9 (preferably phosphoric acid buffer solution at pH 6-7 in 10-100mM concentration) in an amount of 5-100 times based on the afore-mentioned solution and adding peroxidase in an amount of 0.5-10pts. based on 100pts.wt. above-mentioned compound and 30% hydrogen peroxide in an amount of 5-200pts.wt. based on 100pts.wt. above-mentioned compound while dripping or at a time, stirring and reacting the reaction mixture at room temperature for &gt;=1hr, recovering a water-insoluble compound by centrifugation or filtration, washing the recovered compound with water and drying the washed compound. The afore- mentioned water-insoluble substance is capable of inhibiting mutagenicity by direct mutagen without requiring metabolic activation and important for preventing carcinogenesis.
In embodiments, a pre-analyzing computer receives a data record that is created by a wearable medical system (“WMS”) which may implement a wearable cardioverter defibrillator (“WCD”). The WMS has created such data records from patient data captured when the WMS has detected that the patient was having episodes of potential interest for review by clinicians. Before this review, however, the pre-analyzing computer may parse the contents of a received data record and accordingly give it a score. The score may reflect the clinician&#39;s expected preference to review this data record before or after the others. For instance, a low score may be given to data records whose contents are likely not interpretable reliably due to noise or likely of low interest after all. The pre-analyzing computer may then perform a characterizing action with reference to the data record, for facilitating the clinician to find it by its score.
An automated informed consent system uses a computer to inform a patient about a proposed medical procedure and to verify that the patient understands the material presented. The system provides an audiovisual presentation using animation and/or voice-over to aid in the patient&#39;s understanding of the procedure and associated risks. The system comprises a patient interface connected to a network wherein the patient interface includes at least one input device for use by the patient to provide input to the interface and a screen for displaying information to the patient. A server connected to the network in operative communication with the patient interface is also included. The server comprises a program stored in memory and accessible by the patient interface. Once a connection between the patient interface and server has been established, the interface is operable under control of the program to present information concerning a medical procedure to the patient via the screen. The patient interface also requests input from the patient via the input device, and determines from the input whether the patient has achieved a predetermined level of understanding of the information presented. The interface is further operable under the control of the program to generate a consent form for the medical procedure for review by a physician and execution by the patient.
PURPOSE:To provide the titled dental material giving the color of natural tooth when molten, vitrified, cast in the form of a tooth crown, etc. and crystallized, by adding a coloring component comprising the oxide of Fe, Mn, Ce, etc. and optionally a color-developing assistant to a calcium phosphate-based material. CONSTITUTION:The objective dental material is produced by compounding (A) 100pts.wt. of a calcium phosphate-based material having a Ca/P atomic ration of 0.35-1.7 with (B) 0.03-5pts.wt. of two or more compounds selected from the oxides of Fe, Mn, Ce, W, Ti and Ni and optionally (C) &lt;=10pts.wt. of Al2O3, SiO2, etc. as a color-developing assistant. The natural color of tooth can be developed by melting and vitrifying the dental material, casting in the form of a tooth crown or the integrated structure of tooth crown and tooth root, and crystallizing the cast material. The color can be adjusted delicately by selecting the combination and amount of the color-developing components, the amounts of the additives, etc. There is no trouble caused by the dissolution of the colorants.